Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

Sherene Loi(Université Libre de Bruxelles), Stefan Michiels(Université Paris-Sud), Roberto Salgado(Institut Jules Bordet), Nicolas Sirtaine(Institut Jules Bordet), Vinu José(Université Libre de Bruxelles), Debora Fumagalli(Université Libre de Bruxelles), Pirkko Kellokumpu‐Lehtinen(Tampere University Hospital), Petri Bono(Helsinki University Hospital), Vesa Kataja(Kuopio University Hospital), Christine Desmedt(Université Libre de Bruxelles), Martine Piccart(Institut Jules Bordet), Sibylle Loibl(German Breast group), Carsten Denkert(Charité - Universitätsmedizin Berlin), Mark J. Smyth(The University of Queensland), Heikki Joensuu(Helsinki University Hospital), Christos Sotiriou(Université Libre de Bruxelles)
Annals of Oncology
March 9, 2014
Cited by 1,265

Abstract


Related Papers

No related papers found

Powered by citation graph analysis